Skip to main content

ORIGINAL RESEARCH article

Front. Mol. Biosci.
Sec. Metabolomics
Volume 11 - 2024 | doi: 10.3389/fmolb.2024.1407974
This article is part of the Research Topic Metabolomics Perspectives for Clinical Medicine Volume II View all 8 articles

Application of clinical blood metabogram for diagnosis of early-stage Parkinson's disease: a pilot study

Provisionally accepted
Petr G. Lokhov Petr G. Lokhov 1*Oxana P. Trifonova Oxana P. Trifonova 1Elena E. Balashova Elena E. Balashova 1Dmitry L. Maslov Dmitry L. Maslov 1Michael V. Ugrumov Michael V. Ugrumov 2Alexander I. Archakov Alexander I. Archakov 1
  • 1 Institute of Biomedical Chemistry, Moscow, Russia
  • 2 Koltzov Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Moscow Oblast, Russia

The final, formatted version of the article will be published soon.

    In terms of time, cost, and reproducibility of clinical laboratory tests, a mass spectrometric clinical blood metabogram (CBM) enables the investigation of the blood metabolome. Metabogram's components provide clinically relevant information by describing related groups of blood metabolites connected to humoral regulation, the metabolism of lipids, carbohydrates and amines, lipid intake into the organism, and liver function. For further development of the CBM approach, the ability of CBM to detect metabolic changes in the blood in the early stages of Parkinson's disease (PD) was studied in this work. In a case-control study (n = 56), CBM enabled the detection of the signature in blood metabolites related to 1-2.5 clinical stages of PD, according to the modified Hoehn and Yahr scale, which is formed by alterations in eicosanoids, phospholipids and, presumably, in the butadione metabolism. The CBM component-based diagnostic accuracy reached 77%, with a specificity of 71% and sensitivity of 82%. The research results extend the range of disorders for which CBM is applicable and offer new opportunities for revealing PD-specific metabolic alterations and diagnosing early-stage PD.

    Keywords: Metabolomics, clinical blood metabogram, Parkinson's disease, diagnostics, Mass Spectrometry, blood plasma, Clinical metabolomics, personalized metabolomics

    Received: 27 Mar 2024; Accepted: 30 Jul 2024.

    Copyright: © 2024 Lokhov, Trifonova, Balashova, Maslov, Ugrumov and Archakov. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Petr G. Lokhov, Institute of Biomedical Chemistry, Moscow, Russia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.